RxDoctor Payments Data

Rohit Beri, MD

Pulmonary Disease · Waterbury, CTNPI 1881892784

Payments from drug & device makers

$1,986in general payments, 2019–2025

Across 122 payments — averaging $16.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$908
  • Boehringer Ingelheim$140
  • AstraZeneca$101
  • ZOLL Respicardia, Inc.$94
  • Insmed, Inc.$91
  • Shire North American Group Inc$83
  • plus $569 from 16 others

What the payments were for

  • Food & beverage$1,986100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,986 in reported general payments places this provider in the 55th percentile of 255 pulmonary disease providers in Connecticut.

See all pulmonary disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$157,518
Medicare patients
387
Services billed
1,223

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter339$271,235
GlassiaAlpha-1-Proteinase Inhibitor13$166,527
Breo ElliptaFluticasone/Vilanterol309$150,958
NucalaMepolizumab37$136,453
Fasenra PenBenralizumab16$98,923
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr162$91,493
Spiriva HandihalerTiotropium Bromide29$21,795
Spiriva RespimatTiotropium Bromide32$20,342
Incruse ElliptaUmeclidinium Bromide49$17,183
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate70$13,929
Advair HfaFluticasone Propion/Salmeterol36$13,240
Albuterol Sulfate HfaAlbuterol Sulfate489$9,512
Fluticasone-VilanterolFluticasone/Vilanterol26$8,705
Stiolto RespimatTiotropium Br/Olodaterol Hcl15$8,154
DuleraMometasone/Formoterol23$8,005

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Incruse Ellipta$908$667,322896 claims
Takeda Pharmaceuticals U.S.A., Inc.Glassia$67$166,52713 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$140$28,49647 claims
AstraZenecaSymbicort$101$7,39420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 255 pulmonary disease providers in Connecticut.

Other pulmonary disease in Waterbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →